-
Roche To Buy US-listed 89bio For $14.50/shr
-
H.C. Wainwright Starts 89bio Inc. (ETNB) at Buy
-
89bio Inc. (ETNB) PT Lowered to $11 at RBC Capital
-
89bio, Inc. (ETNB) Misses Q2 EPS by 21c
-
89bio Inc. (ETNB) November 10 and 12.50 calls active, share price down 5.9%
-
89bio Inc. (ETNB) PT Lowered to $55 at Cantor Fitzgerald
-
89bio, Inc. (ETNB) Tops Q1 EPS by 3c
-
Goldman Sachs Starts 89bio Inc. (ETNB) at Neutral
-
Cantor Fitzgerald Reiterates Overweight Rating on 89bio Inc. (ETNB)
-
89bio Inc. (ETNB) PT Lowered to $21 at H.C. Wainwright
-
Cantor Fitzgerald Reiterates Overweight Rating on 89bio Inc. (ETNB)
-
89bio, Inc. (ETNB) Misses Q4 EPS by 27c
-
89bio Inc. (ETNB) PT Raised to $37 at Leerink Partners
-
After-hours movers: Nucor, Graco, 89bio Inc
-
89bio Inc. (ETNB) Announces Proposed $250M Underwritten Public Offering of Common Stock and Pre-Funded Warrants
-
H.C. Wainwright Reiterates Buy Rating on 89bio Inc. (ETNB)
-
89bio Inc. (ETNB) Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH
-
89bio Inc. (ETNB) Prices 11.46M Share Offering at $8.5/sh
-
89bio Inc. (ETNB) Announces Proposed $100M Share Offering
-
89bio, Inc. (ETNB) Misses Q3 EPS by 77c
-
89bio Inc. (ETNB) Announces Two Supervisory Board Additions
-
89bio Inc. (ETNB) Appoints Francis Sarena as COO
-
89bio Inc. (ETNB) PT Lowered to $12 at RBC Capital
-
89bio, Inc. (ETNB) Tops Q2 EPS by 8c
-
89bio Inc. (ETNB) Appoints Charles McWherter to its Board

